Author lays out a detailed short-squeeze thesis on ImmunityBio citing ~40% short interest, a cluster of positive catalysts, and improving fundamentals.
IBRX — LONG The author argues IBRX is a perfect short squeeze setup with roughly 40% of float shorted (~120M shares) and about 10 days to cover, so shorts cannot exit fast enough if volume spikes. They cite a cluster of catalysts: positive NSCLC data on Jan 13, Saudi FDA approval on Jan 14, and glioblastoma and CAR-NK data still in the queue, with a new price target of $24. Fundamentals are cited as a floor with revenue up 424% YoY to $32.1M as ANKTIVA ramps and $257M cash on hand removing bankruptcy risk; the author says if $3.00 breaks and holds it will blow up. No specific risk is stated.
Shorts are trapped in a crowded trade (40% SI) while good news keeps dropping daily. If $3.00 breaks and holds, it’s going to blow up from here.
This Reddit post, published January 14, 2026, features u/Bailey-96 discussing IBRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Bailey-96 · Tickers: IBRX